Status:
ACTIVE_NOT_RECRUITING
A Study of RhinAer Stylus for Treating Chronic Rhinitis
Lead Sponsor:
Aerin Medical
Conditions:
Chronic Rhinitis
Eligibility:
All Genders
22-85 years
Phase:
NA
Brief Summary
Post-market study to continue to evaluate the effectiveness of the RhinAer Stylus for chronic rhinitis and the effect of treatment on inflammatory biomarkers.
Detailed Description
Prospective, Open Label, Multicenter Study of the Aerin Medical RhinAer® Stylus for Chronic Rhinitis to continue to evaluate the effectiveness of the RhinAer® Stylus for treating the posterior nasal n...
Eligibility Criteria
Inclusion
- Age 22 to 85 years (inclusively).
- Willing and able to provide informed consent.
- Willing and able to comply with the patient-specific requirements outlined in the study protocol.
- Presenting to the ENT office seeking evaluation and/or treatment for chronic rhinitis (allergic or nonallergic) of at least 12 months duration
- Willing to undergo the RhinAer procedure
- Has a baseline rTNSS symptom score of ≥6 at time of screening
- If on anticoagulation therapy, anticoagulant medications can be withheld during the perioperative period (at least 3-day window pre- and post-procedure).
- Has been diagnosed with either allergic or non-allergic chronic rhinitis and meet the following criteria:
- a. Allergic rhinitis: diagnosed with perennial (non-seasonal) allergic rhinitis and has demonstrated sensitization to specific allergens through skin prick testing, specific IgE blood testing, or other allergy testing methods, confirming the allergic nature of their rhinitis within the past 24 months.
- OR
- b. Nonallergic rhinitis: diagnosed with nonallergic rhinitis with demonstration of a negative skin prick testing, specific IgE blood testing, or other allergy testing methods, confirming the nonallergic nature of their rhinitis within the past 24 months.
Exclusion
- Anatomic obstructions in the nasal passage(s) that in the investigator's opinion limits access to the posterior nasal nerve treatment area.
- Has seasonal rhinitis symptoms.
- Current or recent use of biologic therapy within past 3 months.
- History of chronic epistaxis or has had episodes of significant nose bleeds in the past 3 months.
- Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure.
- Known or suspected to be pregnant or is lactating.
- Has any condition resulting in a predisposition to excessive bleeding (e.g., hereditary hemorrhagic telangiectasia \[HHT\]).
- Has diagnosis of rhinitis medicamentosa, an active nasal or sinus infection or has a history of 'dry eye.'
- Has had previous procedure or surgery for chronic rhinitis (e.g., PNN ablation).
- Has had a nasal or sinus surgical procedure in the past six (6) months.
- Currently participating in another clinical research study or has participated in an interventional study within the past 3 months.
- Has a planned adjunctive procedure at the time of the study procedure or within the 6-month study follow-up period
- Other medical conditions which in the opinion of the investigator would predispose the patient to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study.
Key Trial Info
Start Date :
October 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT06599736
Start Date
October 3 2024
End Date
March 1 2026
Last Update
December 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Colorado ENT & Allergy
Colorado Springs, Colorado, United States, 80923
2
University of Cincinnati
Cincinnati, Ohio, United States, 45267